The 11th Annual Biologics Manufacturing Asia 2024 is Asia’s bioprocessing-focused, knowledge-sharing conference that provides regional biopharmaceutical industry stakeholders a carefully tailored networking platform for leveraging opportunities for strategic collaboration, and exposure to the latest manufacturing technologies and know-how.
We have an agenda built around success stories from Asia’s biopharmas as well as the technical expertise from International Biopharmas and BIG Pharmas, presentations on the latest manufacturing technologies such as single-use and end-to-end continuous processing for biologics, today’s challenges and opportunities in biomanufacturing, advances in upstream process development, cost-optimization strategies in downstream processing, analytical characterization strategies, facility design, and scale-up strategy, fill & finish innovation to streamline the operations amongst other crucial themes.
The BMA 2024 is co-located with 8th Annual Biologistics World Asia 2024, 2nd Clinical Trial Festival Asia 2024 and Asia-Pacific Bioprocessing Excellence Awards Gala Dinner 2024.
Seat Yee Lau
Niki Wong – Keynote
Wolfram Carius – Keynote
Kai Yin Po
Jong Hyuk Lim
We have an agenda built around success stories from Asia’s biopharmas as well as technical expertise from international biopharmas and Big Pharmas, presentations on the latest manufacturing technologies such as single use and continuous processing for biologics, key challenges in cell therapy manufacturing, cost-reduction strategies in downstream processing, sustainability case studies surrounding single use systems, discussions on vaccine manufacturing, know-how on the developments in pathogen safety amongst other crucial themes.
The 11th Annual Biologics Manufacturing World Asia is the largest and the ONLY bioprocess business and technology convention in Asia Pacific! In 2024, 1000+ biomanufacturing stakeholders from Big Pharmas, Biopharmas, Contract Manufacturing Organisations, Academic & Research Institutes, Regulatory Authorities, Solution Providers across Singapore, China, South Korea, Taiwan, Japan, Australia, India, and SouthEast Asia, will convene hybridly to discover, discuss and debate about biologics manufacturing processes, best practices and latest developments to manufacture biologic drugs cheaper and faster!
Explore the most comprehensive upstream processing from early cell isolation and cultivation, cell line engineering, media development, raw materials considerations and more for enhancing and optimizing cell culture return and production rate with cost-reduction strategy. Know-how on the latest development of upstream processing technologies have evolved and potentially changed the biologics drug manufacturing process to be more economically feasible.
Immerse into the most focused biologics downstream processing with the ultimate goal of meeting quality and purity requirements of biologics drug products. Multiple purification approaches, concentration, product recovery, cost reduction and optimizing the integration of continuous manufacturing and utilization of single use disposable systems to optimize biologics manufacturing process production rate will be discussed.
Analytics & Quality
Innovative strategy of assay optimization, real time monitoring system with highest compromisation to quality control of biologics products to a direction of improving efficiency while advocating process automation are the keys to quicker market commercialization and regulatory compliance. Topics built around cost and process optimization with latest developments in analytics and quality to foster biologics enhancement.
Facility Design, Tech-Transfer & Scale-Up Strategy
Understand the challenges and the trends of biomanufacturing facility design in detail and find out the best practices of formulation and bulk technology transfer for optimizing output while maintaining quality and activity of products. Emphasis on scaling up processes without compromising product quality while discussing the latest technology and solution to scale up for maximum output.
Emerging Technologies and Applications
Identify the most imminent trends on the emerging technologies and applications with the potential to enhance and fasten the biologics manufacturing process. Applications such as PAT tools, novel technologies in single-use technologies and continuous processing, as well as automation and bioprocessing 4.0 to fasten the biologics manufacturing process will be discussed.
Ajinomoto Genexine is providing customers with the CELLiST™ series developed based on Ajinomoto's media manufacturing technology and know-how,
which has been researching serum-free media for over 30 years, through a number of domestic and overseas agencies. https://en.ajinomotogenexine.
MasterControl Inc. is the leading provider of cloud-based quality and compliance software for life sciences and other regulated industries. Our mission is the same as that of our customers – to bring life-changing products to more people sooner.
You can use the MasterControl Product Lifecycle Excellence™ platform to digitize, automate and connect quality and compliance processes at every step – from concept to commercialization. Join over 1,000 companies worldwide that rely on MasterControl solutions to achieve new levels of operational excellence across product development, clinical trials, regulatory affairs, quality management, supply chain, manufacturing and postmarket surveillance.
Learn more at www.mastercontrol.com
Sartorius Stedim Biotech is a leading partner of the biopharma industry. Our solutions support our customers in producing drugs safely, timely and economically. The key product categories of our company are cell cultivation, fermentation, filtration, purification, and fluid management.
Pfanstiehl is the market leader of high purity, low endotoxin, low metal excipients for biologics, biosimilars, vaccines, cell culture media and injectable (liquid and lyophilized) formulations and supplies its products to nearly all leading global biopharmaceutical companies.
Pfanstiehl was founded in 1919 and currently celebrating its 103rd anniversary year in 2022. Pfanstiehl is headquartered at Waukegan, IL, USA and has diverse global technical support team across the globe in USA, Europe & APAC.
Pfanstiehl has manufactured parenteral grade excipients for more than 50 years, and Pfanstiehl’s high purity, low endotoxin and low metal excipient products are known as “best in class” due to their high characterization, performance, consistency, and quality attributes.
Pfanstiehl’s excipients are critical components in the majority of the global blockbuster biopharmaceutical drugs and vaccines including majority of the Covid -19 vaccines that were administered globally.
- The 3M biopharmaceutical business is a subset of the 3M Separation and Purification Sciences Division which utilizes cutting edge 3M material science that pushes the boundaries of purification, filtration, and separation to support production, processes that change lives, and deliver quality solutions where it matters most.
- Our biopharma and materials science expertise can help you improve in-process purity, increase the yield of your product and lower manufacturing costs – so you can focus on bringing life-saving treatments to trial and market
- Biopharmaceutical Purification | 3M
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.
For more information, please visit www.thermofisher.com
AGC Biologics is a global CDMO with seven facilities worldwide providing process development and manufacturing services for protein-based biologics and advanced therapies. From development to clinical trials, to full-scale commercialization, we can help you reach your goals at any stage in the development or manufacturing process. We specialize in the following modalities and substances, mammalian and microbial-based therapeutic proteins, recombinant DNA, plasmid DNA (pDNA), viral vectors, messenger RNA (mRNA), and genetically engineered cells. Our services range from Process Development, Analytical Development, cGMP Manufacturing (both clinical and commercial), Quality Control, and Quality Assurance and Process Validation.
Bio-Rad Laboratories is a leading provider to the life science and clinical diagnostics markets where the company’s products are used for scientific discovery, drug development, and biopharmaceutical production. Bio-Rad’s long-lasting customer relationships foster the company's research and development efforts and inspire the introduction of innovative products and solutions that accelerate the discovery process and improve healthcare. The Protein Purification Business, part of the Life Science Group at Bio-Rad, provides researchers with the chromatography tools they need to isolate and purify proteins from discovery through clinical trials into bioprocess manufacturing. With more than 60 years of purification experience, Bio-Rad continues to expand solutions to streamline the drug discovery and development process.
Bio-Rad Laboratories, Inc.
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics from concept to commercialization for the benefit of patients worldwide.
With over 10,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of June 30, 2022, WuXi Biologics is supporting 534 integrated client projects, including 14 in commercial manufacturing.
WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to become an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.
GenScript is a global biotechnology group. GenScript’s businesses encompass four major categories based on its leading gene synthesis technology, including operation as a Life Science CRO, enzyme and synthetic biology products, biologics development and manufacturing, as well as cell therapy.
Founded in 2002 and listed on the Hong Kong Stock Exchange in 2015, GenScript has an established global presence across Greater China, North America, the EU, and Asia Pacific. Today, over 300,000 customers from over 160 countries and regions around the world have used GenScript’s premier, convenient, and reliable products and services.
GenScript currently has more than 3000 employees globally, 33% of whom hold master’s and/or Ph.D. degrees. In addition, GenScript has a number of leading commercial technologies developed in the fields of synthetic biology, immunotherapy, antibody design, chemical synthesis and bioinformatics, including more than 70 patents and over 200 patent applications. As of January 2019, GenScript's products and services have been cited by 36,500 scientific papers worldwide.
GenScript is committed to striving towards its vision of being the most reliable biotech company in the world to make humans and nature healthier through biotechnology.
For more information, visit www.genscript.com
Evonik is one of the world leaders in the specialty chemicals industry. Active in more than 100 countries around the world, Evonik goes far beyond chemistry to create innovative, profitable and sustainable solutions for customers. We contribute small amounts of material that make a big difference. We provide the highest quality cell culture media ingredients for biologic drugs development & manufacturing, produce lipid nanoparticles essential in mRNA-based COVID-19 vaccines, make tires more fuel-efficient, and animal feeds healthier. As one of the key growth regions, Evonik has a strong production and R&D footprint in Asia Pacific. With over 5,000 employees at more than 50 production sites, the region contributed to €3.4 billion sales in 2021.
At Evonik, we offer high-quality cell culture solutions to pharmaceutical and biotech companies to help them boost cell culture performance in the manufacturing of therapeutic proteins like monoclonal antibodies, as well as in the production of viral vectors such as the adeno associated viral (AAV) vectors for gene therapy.
Commercially proven for reliable media performance across countless biological programs, our cQrex® portfolio features a range of peptides and keto acids designed to address key issues in mammalian cell culture.
Our latest offering, plant-derived cholesterol PhytoChol® Biopharma, which has been especially developed for use in animal-free cell culture media formulation, for example in chemically defined media which do not use fetal bovine serum (FBS). In addition, specialty carbohydrates like D-Mannose can be used as alternative energy sources and building blocks for intracellular protein glycosylation, enabling a higher flexibility in the production of therapeutic proteins.
All these cell culture ingredients are non-animal derived, readily available at commercial scale and can be customized to address specific project needs.
Learn more about Evonik’s cell culture expertise at https://healthcare.evonik.com/en/biopharma/cell-culture.
Tofflon Science and Technology Group Co. Ltd. was established in 1993 and is a one-stop solution provider for bio/pharmaceutical industry. Besides being a comprehensive pharmaceutical equipment supplier, Tofflon also provides process support, core equipment, integrated systems, pharma engineering (Modular construction & Site build construction) and consumables such as media, resin and single use systems for the pharma and biotech industry around the world.
Since founded, Tofflon has supplied and supported more than 12,000 sets of equipment and systems for 3,000 pharmaceutical companies across over 50 countries and regions in the world which have been widely applied in the fields of R&D, liquid and lyo injectables, chemical API, bioengineering and pharma packaging. Tofflon has also been approved with all the international regulatory certifications like German TUV ISO9001, ISO14001, OHSAS 18001, CE, UL, ASME, PED, etc.Today, Tofflon Science and Technology Group Co. Ltd has over 5500 employees around the globe with a total asset of over 2 billion USD. The company currently has several R&D centres around the world (China, Italy and Germany) and is expanding further. Through our Technological Innovation and Development Concept: Automation, Intelligence, Modularization, Continuous Processing and System Integration, we create values for the industry and our partners: cGMP compliance, High Efficiency, Automation, Simple Interface, Cost Effective, Easy Validation, Integrated Service, and Faster Time to Market.
ABER is the market leader in bio-capacitance sensors with unparalleled experience and expertise in the field, boasting a world class team to guide users in finding effective solutions to their process monitoring needs.
With over 35 years’ experience as a global contract service organization, SGS provides integrated (bio)pharmaceutical development and testing solutions including clinical research, pharmaceutical development, biologics characterization, biosafety, and quality control testing for small and large molecules, raw materials, containers and finished products.
SGS provides a comprehensive range of biosafety services such as: virology, cell and molecular biology, microbiology and TEM. Health Authorities (US FDA and the EMA), require companies to undergo safety testing demonstrating that cell banks, viral banks, raw materials, bulk harvests, and batches of clinical drug are free of bacteria, fungi, mycoplasma, viruses and other potential contaminants. SGS ensures product safety in satisfying these regulatory requirements.
Terumo Pharmaceutical Solutions develops patient-oriented parenteral delivery solutions for therapeutic performance and safety Globally trusted for quality and precision, Terumo Pharmaceutical Solutions offers pharmaceutical and medical device manufacturers around the world comprehensive product design and development services, for primary container, injection, infusion therapy devices, and contract development and manufacturing services (CDMO).
We have decades of experience collaborating with pharmaceutical companies from the earliest phases of drug development to product commercialization to optimize critical aspects of parenteral
drug delivery. Innovation and creativity are central to our value proposition. Our expert teams lead the industry in developing and manufacturing advanced, high-performing infusion and injection technologies for
all parenteral applications. We provide sterile injectable contract development and manufacturing (CDMO) services from initial combination device design and formulation development to commercial manufacturing.
supporting better patient outcomes around the world.
We listen. We question. We deliver.
“PharmNXTBiotech is a young Biotech Start-up based in Mumbai, it was established in the year 2017 with the idea of creating end-to-end bioprocess solutions and providing niche technologies to help reduce manufacturing costs for critical lifesaving drugs.
We recently inaugurated PharmNXTEkuse our brand new state-of-the-art single manufacturing facility based in Pune, which houses end-to-end solutions for the biopharma, vaccines manufacturing and containment solutions.
With the vision of “Make in India for the World,” we are ready to showcase our Xelta range of Single Use 2D, 3D bags and NXTmix Levitating mixing solutions along with our hardware technologies for downstream processing.
For containment solutions, we have our Make in India products: Flexible Isolators, Rigid Isolators as well as Powder Transfer Bags to handle potent molecules.”
Since its inception, Hanbon Technology has been adhering to the original intention to provide biopharmaceutical users with drug purification equipment and services based on chromatography technology. The main products are: Biopharmaceutical downstream purification equipment, Industrial preparative liquid chromatography systems, Supercritical fluid chromatography systems, Continuous chromatography systems, Small nucleic acid synthesis and purification equipment, and can provide users with chromatography products as the core of the overall solutions and services. For more than 20 years, Hanbon has been following the wave of biopharmaceutical development, constantly developing new products and meeting the emerging needs of the market, providing R&D and production equipment for synthesis, purification and delivery of emerging small nucleic acid drugs, mRNA vaccines, cell therapy drugs, etc.
Website link: http://www.hanbon.com.cn/en/
Gerresheimer is the global partner for pharmaceutics, biotech, healthcare and cosmetics with a very broad product range for pharmaceutical and cosmetic packaging solutions and drug delivery systems. The company is an innovative solution provider from concept to delivery of the end product. Gerresheimer achieves its ambitious goals through a high level of innovative strength, industrial competence and concentration on quality and customer focus. In developing innovative and sustainable solutions, Gerresheimer relies on a comprehensive international network with numerous innovation and production centers in Europe, America and Asia. Gerresheimer produces close to its customers worldwide with around 11,000 employees and generated annual revenues in 2021 of around EUR 1.5b. With its products and solutions, Gerresheimer plays an essential role in people's health and well-being.
IKA is a leading manufacturer of laboratory equipment, analytical and process technology. Headquartered in Germany, we opened our first subsidiary in the U.S. in 1985. After a decade of steady growth in the world markets, the first Asian subsidiary was founded in Malaysia in 1995 to serve the booming Asian market. From then onwards, the IKA Group kept growing and continues to grow to this day. In 1998, the Chinese subsidiary in Guangzhou was added, which has since expanded to include sales offices in Beijing and Shanghai. IKA Works Japan and IKA India, as well as branches in Brazil, South Korea, Vietnam, Great Britain, Poland, Thailand and Turkey followed some time later. Today, a total of 15 branches in 13 countries ensure excellent service worldwide.
Our website: www.ika.com
Emerson is where technology and engineering come together to create solutions for the benefit of our customers, driven without compromise for a world in action. As a global innovator, Emerson has a deep legacy of solving the most complex challenges facing modern life. We combine advanced technologies, industry-leading expertise and an insatiable curiosity about the world around us to create sustainable solutions for the essential customers we serve.
Our how is complex, but our why is simple and found in our unified global Purpose: We drive innovation that makes the world healthier, safer, smarter and more sustainable. https://www.emerson.com/en-sg/
Harro Höfliger develops and manufactures production and packaging equipment for customers around the world. Pharmaceutical and medical companies as well as brand item manufacturers for consumer and home care products trust in our highly specialized process solutions. Our portfolio of machines covers every industrialization level, and our broad range of services focus on the entire product life cycle
Present your expertise to the Asian Bioprocessing industry’s key stakeholders through a variety of available speaking packages.
Join the exhibition, and build an impressive presence among your potential clients.
Emphasize on your messages by promoting your brand alongside exhibition and thought leadership.
Engage with and build lasting connections that matter the most to your business.
Gain exclusive access to contacts of high-profile attendees through intimate networking opportunities.